Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia

Clinical Rheumatology

Volumn 16, Issue 3, 1997, Pages 291-295

  Skeith, K J ^a   Hussain, M S ^a   Coutts, R T ^a   Ramos Remus, C ^a   Avina Zubieta, J A ^a   Russell, A S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adverse Effects; Fibromyalgia; P450IID6 Polymorphism

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DEBRISOQUINE; DESIPRAMINE; DICLOFENAC; FLUOXETINE; IMIPRAMINE; INDOMETACIN; MUSCLE RELAXANT AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; SPARTEINE;

ADULT; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DATA ANALYSIS; DETOXIFICATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; ENZYME SUBSTRATE; FEMALE; FIBROMYALGIA; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; HYPERALGESIA; MALE; MUSCLE RELAXATION; PHENOTYPE; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS;

ADULT; ANALGESICS; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACK PAIN; CANADA; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; FEMALE; FIBROMYALGIA; HUMANS; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PREVALENCE;

EID: 0030955662     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02238966     Document Type: Article

References (28)

1. Wolfe F, Smythe HA, Yunus MB et al. The American College of Rheumatology 1990 Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
2. Smythe HA: Fibrositis as a disorder of pain modulation. Clin Rheum Dis 1979;5:823-32.
3. Qiao ZG, Vaeroy H, Morkrid L. Electrodermal and microcirculatory activity in patients with fibromyalgia during baseline, acoustic stimulation and cold pressor tests. J Rheumatol 1991;18:1383-9.
4. Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA: A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum 1988;31:1535-42.
5. Carette S, McCain GA, Bell DA, Fam A. Evaluation of amitriptyline in primary fibrositis. Arthritis Rheum 1986;29:655-9.
6. Jacobsen S, Danneskiold Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 1991;20:294-302.
7. Drewes AM, Andreasen A, Nennum P, Nielsen KD. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol 1991;20:288-93.
8. Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 1985;12:980-3.
9. Yunus MB, Masi AT, Aldag JC. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J Rheumatol 1989;16:527-32.
10. Wysenbeek AJ, Mor F, Lurie Y, Weinberger A. Imipramine for the treatment of fibrositis: a therapeutic trial. Ann Rheum Dis 1985;44:752-3.
11. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, Edworthy SM, Baron M, Koehler BE, Fam AG, Bellamy N, Guimont C. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994;37:32-40.
12. Alvan G: Clinical consequences of polymorphic drug oxidation. Fundam Clin Pharmacol 1991;5:209-28.
13. Mortimer O, Lindstrom B, Laurell H, Bergman U, Rane A. Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br J Clin Pharmacol 1989;27:223-7.
14. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: cosegregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
15. Hussain MS. Thesis. Edmonton, Alberta, Canada, University of Alberta 1992.
16. Wijnands M, Van Riel P, Van't Hof M, Gribnau F, van de Putte L. Long-term treatment with nonsteroidal anti-inflammatory drugs in rheumatoid arthritis: a prospective drug survival study. J Rheumatol 1991;18:184-7.
17. Wolfe F, Cathey MA, Kleinheksel SM et al. Psychological status in primary fibrositis and fibrositis associated with rheumatoid arthritis. J Rheumatol 1984;11:500-6.
18. Goldenberg DL. Psychiatric and psychologic aspects of fibromyalgia syndrome. Rheum Dis Clin North Am 1989;15:105-14.
19. Meyer UA, Skoda RC, Zanger UM. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. Pharmacol Ther 1990;46:297-308.
20. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Nisnik HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991;40:63-8.
21. Brosen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism in the metabolism of imipramine. Clin Pharmacol Ther 1991;49:609-17.
22. Derenne F, Joanne C, Vandel S, Bertschy G, Volmat R, Bechtel P. Debrisoquine oxidative phenotyping and psychiatric drug treatment. Eur J Clin Pharmacol 1989;36:53-8.
23. Lario BA, Teran J, Alonso JL, Alegre J, Arroyo I, Viego JL. Lack of association between fibromyalgia and sleep apnoea syndrome. Ann Rheum Dis 1992;51:108-11.
24. Goldenberg DL. A review of the role of tricyclic medications in the treatment of fibromyalgia syndrome. J Rheumatol 1989;19 (suppl):137-9.
25. Balant Gorgia AE, Balant L, Zysset T. High plasma concentrations of desmethylclomipramine after chronic administration of comipramine to a poor metabolizer. Eur J Clin Pharmacol 1987;32:101-2.
26. Brosen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991;32:136-7.
27. Lavrijsen KL, Heykants JJ. Narcotic analgesics and debrisoquine polymorphism. Anaesthesiology 1989;71:474-5.
28. Veronese ME, McLean S. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype. Eur J Clin Pharmacol 1991;40:547-52.